Published online in http://ijam.co.in ISSN No: 0976-5921

International Journal of Ayurvedic Medicine, Vol 14 (1), 2023; 42-49

Herbs used in cardiovascular diseases

Review Article

Falakaara Saiyed[1*], Rajesh Maheshwari[2], Dilsar Gohil[3], Krupa Joshi[4]

1. Assistant Professor, 2. Professor, 3. Assistant Professor, 4. Assistant Professor, Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At & Po. Piparia, Taluka Waghodia, Dist. Vadodara, Gujarat, India.

Abstract

One of the many therapeutic uses for herbal medicines is the treatment of cardiovascular diseases. Since medications from traditional systems of medicine do not require official regulatory agency approval or clinical testing before going on the market, they are less frequently proven to be safe and effective than conventional pharmaceuticals. In this review, we summarize the ongoing information on homegrown medicines, essentially utilized in cardiovascular treatment. We show how there is frequently no scientific evidence to support the use of these medications to treat cardiovascular disorders. Despite the fact that they seem to affect organic cycles connected with the cardiovascular framework, there is little data on the restorative impacts of the majority of these herbs. Concerns are raised by the potential for medication contamination or drug substitution with other prescriptions and related negative effects like a higher risk of drug interactions. Doctors should review any potential benefits and drawbacks of their patients' use of herbal remedies in every situation.

Key Words: Herbs, Medicine, Cardiovascular disease, Potential benefits, Drawbacks.

Introduction

Herbs have been used medicinally for a very long time, and the practice is still common today. According to a recent survey, one in five Americans has used herbal or nutritional supplements at some time in their life. As per gauges, more than 25% of currently promoted medicines come from plants utilized in conventional medication (1). Prevalence rates are substantially higher in impoverished countries due to a more marked history of herbalism and restricted access to essential medications. For instance, traditional Chinese herbs are utilized to make 30% to 50% of the medications used in China (2). Compared to other medical disciplines, cardiovascular medicine has seen a stronger uptake of herbal remedies (3). The most successful drugs have had their effects thoroughly analyzed; some of them have even gone on to become historical pillars in the treatment of cardiovascular illness. This holds true for medications like reserpine, which was derived from the plant *Rauwolfia serpentina* L. and was initially used to treat schizophrenia, digoxin, and digitoxin, which were derived from the plant's *Digitalis lanata* and *Digitalis purpurea*, as well as acetylsalicylic acid (aspirin), which was extracted from willow bark. All prescriptions at times cause more harm than anything, especially ones got from plants. The account of digoxin and reserpine is normal in such a manner. The signs for the two medicines have consistently declined to owe to their confined restorative reach unfavourable impacts, notwithstanding assuming a critical part following their discovery (4). The objective of this exploration is to spread out information on the viability and security of the herbal drugs most frequently utilized in cardiovascular treatment and to determine the guidelines controlling their utilization.

*** Corresponding Author:**

Falakaara Saiyed

Assistant Professor, Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, At & Po. Piparia, Taluka Waghodia, Dist. Vadodara, Gujarat, India. 391760

Email Id: falakaara2908@gmail.com

Regulation of Herbal Medications

The use of herbal remedies is linked to many prevalent disorders. The effectiveness and safety of herbal remedies are often contested since they are subject to a different regulatory procedure than conventional medications. Herbal medicines are controlled by the Food and Drug Administration (FDA) in the US as "dietary enhancements". The main features of this rule are as follows: Herbal medications do not need FDA clearance prior to sale and are not required to be proven safe or efficient for treating a specific disease or condition. The FDA is primarily responsible for ensuring the safety of these medications by reviewing reports of serious adverse effects submitted through the Safety Reporting Portal by the manufacturer, consumers, or medical professionals. The FDA should make an implementation move against a dietary enhancement item once it stirs things up around town. If the FDA observes that an item is perilous, it might sue the producer, issue an admonition, or solicitation that the item is eliminated from the market. Due to this, herbal

medications are not required to undergo clinical testing prior to being approved in the United States, and they may only be labelled dangerous after harm has already been done (5). While the European Medicines Agency has illustrated administrative methods as a perspective for the showcasing approval or enlistment of natural restorative items, the permitting and promoting of herbal remedies in the European Union are constrained by the regulation of the individual member states (6). These methods give that no clinical testing or viability and security review are essential on the off chance that an item has been in need for no less than 15 years in the European Union ("traditional use registration"), but that other herbal products must show they are effective and have an "acceptable" level of safety (7). Doctors should be aware of the possible side effects and indications connected with the use of herbal medications. However, since doctors are unaware of the effects of herbal medications and patients often underreport their symptoms, it may be difficult for them to accurately identify new signs or symptoms. Only approximately 70% of patients inform their physicians about the supplements they use, making it hard for medical professionals to consistently compile reliable statistics on supplement consumption. Since herbal treatments are supposed to be safe and are not considered to be pharmaceuticals, patients genuinely believe there is no need to record their use, but clinicians do not give enough care to the therapeutic implications of such preparations. Furthermore, there are severe concerns about the security and effectiveness of concurrent therapy since the use of herbal medicines has been connected to a failure to follow conventional prescriptions.

To solve this issue, doctors need to interview patients systematically. The clinical setting must be taken into consideration while evaluating signs and symptoms, and information about the use of legitimate medications, herbal treatments, and other preparations must be correctly recorded. Correspondence with the patient is a vital piece of the interaction, and it ought to occur while examining the benefits and impediments of specific herbal treatments as well as their risk-benefit proportion. The patient should eventually be given the option to quit taking a novel herbal medication. Another critical concern is the education of medical professionals. The study of alternative medicine is no longer required in the majority of Western countries' medical school curricula, and there are no longer any requirements for consultation. Accordingly, it is altogether dependent upon the specialist to choose whether to acquire the important information in the field to furnish their patients with better consideration. In the end, medical professionals and patients may need to consult specific websites maintained by governmental and regulatory bodies that offer information sources that are typically current and reliable and can frequently fill the informational void left by scientific societies.

Different Herbs Used for treating cardiovascular diseases

From the list of disorders that may have been triggered by complementary medicine maintained by the National Center for Complementary Medicine, the selection of any cardiovascular problem was done (8). The research examines 42 herbal treatments and points forth possible applications for them. This review will concentrate on the following cardiovascular diseases: hypertension, peripheral artery disease, heart failure, coronary artery disease, dyslipidemia, and thromboembolic disorders. Additionally, we selected herbal medicines that might be effective in treating at least one of these ailments. Asian ginseng (*Panax ginseng*), astragalus (*Astragalus membranaceus*), flaxseed oil (*Linum usitatissimum*), garlic (*Allium sativum*), ginkgo (*Ginkgo biloba*), grape seeds (*Vitis vinifera*), green tea (*Camellia sinensis*), and hawthorn (*Crataegus laevigata*) were among the ten herbal treatments selected (*Glycine max*) (9).

Asian Ginseng (*Panax ginseng*)

Asian ginseng is a characteristic adaptogen that the body utilizes to support immunity and large well-being. Asian ginseng is thought to provide several health advantages, including the capacity to control cholesterol, blood sugar, and blood pressure levels (10). Asian ginseng includes saponins termed ginsenosides that have a partial agonistic impact on steroidal receptors, according to preclinical findings from in vitro and in vivo investigations. By enhancing the release of nitric oxide (NO) from endothelial cells, altering calcium ion channels in myocardial cells, decreasing the formation of reactive oxygen species, and raising platelet adhesion, these saponins may have beneficial effects on the cardiovascular system (11). The therapeutic benefits of taking Asian ginseng in populations of persons with cardiovascular issues have only seldom been the subject of major, high-quality clinical studies. A generally late exhaustive survey and meta-examination of 17 randomized clinical trials (RCTs) found that Asian ginseng obviously affected systolic, diastolic, or mean arterial blood pressure (12). Ginseng's viability in treating type 2 diabetes was analyzed in a meta-examination of 8 investigations. There was no way to see a distinction in glycosylated veils between the Asian ginseng supplementation and the benchmark groups, despite the fact that few optional results, including fasting glucose, postprandial insulin, insulin resistance, triglycerides, total cholesterol, and low-density lipoprotein (LDL) levels, seemed to get to the next level (13). In a past careful examination that included 16 RCTs directed in individuals with and without diabetes, there was no perceptible impact of this spice on HbA1c levels, fasting plasma insulin, or insulin resistance (14). Although there does not currently seem to be enough evidence to back this claim, Asian ginseng may be useful in treating cardiovascular diseases. Safety concerns. It has been shown that Asian ginseng increases the activity of cytochrome P450 (CYP450) family enzymes, which in turn lowers the bioavailability of several medications,

including warfarin (15). Asian ginseng seems to be generally safe when used in the recommended amounts and for a brief length of time. Long-term use might cause increased blood pressure, nausea, diarrhea, migraines, insomnia, and allergic reactions, to give some examples of conceivable incidental effects.

Astragalus (*Astragalus membranaceus*)

Astragalus is utilized as a safe framework for immune system stimulants and as an adjunctive treatment for upper respiratory problems and the normal common cold virus. Experimental evidence from in vitro and in vivo studies suggests that astragalus' antioxidant and anti-inflammatory properties may have a favorable effect on cardiomyocytes (16). It may lessen the cardiac hypertrophy brought on by isoproterenol in rat models and seems to correct the mitochondrial dysfunction brought on by angiotensin II in rat vascular smooth muscle cells (17,18). This plant's anti-oxidant properties seem to be crucial in mediating this activity (19). Astragalus has also been shown to have a cardioprotective effect on viral myocarditis in cell cultures and animal models (20).

Astragalus has been tracked down in clinical exploration to improve electrocardiographic parameters and cardiovascular results in little observational examinations incorporating patients with congestive heart failure and ischemic coronary disease as well as to mitigate the side effects of dyspnea, chest agony, and angina. (21-24). However, it is not possible to access the English-language version of these documents. Based on information from reliable clinical trials examining astragalus' efficacy and safety in the treatment of cardiovascular illnesses, there have not been any safety concerns raised yet. The security profile of astragalus in cardiovascular patients is obscure because of an absence of satisfactory wellbeing proof (25,26).

Flaxseed Oil (*Linum usitatissimum*)

The significant amount of soluble fiber in flaxseed makes it a popular laxative. One or more of the possible health advantages of flaxseed and flaxseed oil includes the reduction of symptoms associated with arthritis, osteoporosis, menopause, and cancer prevention. Numerous potential benefits for cardiovascular well-being have been attested, including bringing down blood pressure and cholesterol levels, deferring the beginning of atherosclerosis, and forestalling arrhythmias (27).

Flaxseed has a significant amount of alpha-linolenic acid, an essential n-3 polyunsaturated fatty acid that may have beneficial effects on coronary artery disease, metabolic syndrome, hyperlipidemia, and inflammation (28). Moreover, flaxseed contains lignans, which have anti-oxidants and phytoestrogen properties, and is a wellspring of both solvent and insoluble fiber. The two parts are known to bring down blood lipid levels by empowering the discharge of bile acids from the fecal waste and forestalling the production of endogenous cholesterol (29).

Flaxseed may decrease growth and encourage the regression of atherosclerotic plaques, according to research conducted on animals (30). Flaxseed's anti-inflammatory properties, which may possibly decrease platelet and endothelial reactivity and expansion, would be answerable for the antiatherogenic benefits that have been reported (31). A genuinely huge, however unassuming, decline in both systolic blood pressure (SBP) (- 1.77 mm Hg) and diastolic blood pressure (DBP) (- 1.58 mm Hg) was found in the treatment bunch in a meta-examination of 11 controlled trials with 1,004 members treated with entire flaxseed or items got from flaxseed for 3 to 48 weeks (32). Patients with peripheral artery disease who consumed 30 g of flaxseed daily saw their blood pressure drop more than those who took a placebo (33). This gainful flaxseed impact is by all accounts basically made sense of by a diminishing in circulating oxylipins, which are notable controllers of vascular tone and inflammation (34,35).

Supplementation with flaxseed or its derivatives substantially reduced total and LDL cholesterol in 1,539 persons in a meta-analysis of 28 RCTs (34). Triglycerides and high-density lipoprotein (HDL) cholesterol were unaffected by flaxseed. This evaluation covered clinical studies that used a variety of interventions, doses, demographics, and methodological quality. Contrasting flaxseed with a placebo, an example of patients with peripheral artery illness had a 15% decrease in blood levels of LDL cholesterol. The impact of flaxseed in diminishing ventricular arrhythmias in people has not yet been examined, in spite of information from concentrates on creatures that proposes flaxseed and its bioactive parts might abbreviate the QT interval and the length of the heart's action potential (36). Flaxseed was many times all around endured in clinical examinations. Because of its high fibre content, flaxseed has been connected to digestive issues including diarrhea and constipation. It could hinder oral medications from being effectively absorbed by the digestive system, reducing their efficacy(37).

Garlic (*Allium sativum*)

Infections, cancers, and cardiovascular issues are just a few of the diseases that garlic has long been known to cure and prevent. Blood triglyceride and cholesterol levels as well as platelet aggregation are reduced by garlic in particular medical and biological information Garlic has been suggested to have anti-atherosclerotic properties through lowering artery fat buildup and inflammatory and oxidative pathways (38). Garlic may straightforwardly influence a few natural components connected to the etiology of hypertension, including oxidative stress, endothelial NO production, and hydrogen sulfide generation. These biological mechanisms may result in reduced peripheral vascular resistance, vasodilation, and relaxation of smooth muscle cells. Intestinal absorption and endogenous cholesterol synthesis have both been demonstrated to be reduced by garlic. Finally, research on diabetic animal models has shown that garlic helps reduce blood glucose levels (39). Several observational and experimental clinical studies have shown that garlic may be useful in treating human hypertension, although

the results were conflicting. Garlic has been demonstrated in several human clinical studies to lower blood cholesterol levels. A meta-examination of 39 significant preliminaries demonstrated that taking garlic supplements for a very long-time diminished total and LDL cholesterol by 10% while perceptibly affecting HDL cholesterol or triglycerides in those with blood cholesterol levels higher than 200 mg/dl. As per RCT information, garlic didn't improve clinical results in people with arterial peripheral occlusive disease.

Garlic diminishes fasting blood glucose levels, as indicated by a meta-examination of seven RCTs including both normal people and people with diabetes (40). A relatively recent pilot study of people with type 2 diabetes found that supplementing with garlic had no impact on their metabolic parameters, including insulin resistance, nor did it improve their endothelial function, vascular inflammation, or oxidative stress (41). However, this finding was not confirmed. There is not enough evidence to claim that garlic is a successful treatment for cardiovascular illnesses, despite some hopeful outcomes. A couple of the systemic issues with RCTs of garlic for the treatment of cardiovascular issues incorporate little sample sizes, restricted research spans, an absence of statistical power, lacking randomization, an enormous level of variety in garlic arrangements, and uneven measurements. Despite the fact that the security profile has not been very much assessed in many examinations, garlic supplementation is by all accounts commonly safe for people. The most continuous terrible impacts are heartburn, nausea, vomiting, poor breath, and body odour. Because of the potential antiplatelet action that garlic might have, it ought to be taken with intense caution in patients who are on antiplatelet or anticoagulant drugs (42).

Ginkgo (*Ginkgo biloba*)

GINKGO (*Ginkgo biloba*) leaf extract has been utilized broadly for a long time to treat bronchitis, fatigue, and tinnitus. For its capacity to improve memory and cognition as well as for its potential to prevent and treat dementia and coronary heart disease, ginkgo has recently attracted a lot of interest (43). The main components of ginkgo leaf extract are flavonoids, bilobalide, and ginkgolides, which have antioxidant, anti-inflammatory, and platelet-inhibiting properties (44). Gingko has been displayed to change endothelial NO release and inhibit the angiotensin-converting enzyme in animal studies (45). Gingko, however, has not yet been scientifically shown to be useful for treating people with hypertension (46).

Researchers found no proof that ginkgo diminished complete or cardiovascular illness mortality, or cardiovascular occasions including myocardial infarction, angina pectoris, and stroke when contrasted with placebo treatment in an enormous RCT with north of 3,000 members noticed for a normal of more than 6 years. Additionally, multiple clinical studies have shown that ginkgo may help with symptoms in people with peripheral artery disease; however, more recent RCT data did not support this claim (47). Various unwanted effects of ginkgo have been discovered via clinical studies, including headache, nausea, diarrhoea, disorientation, and skin rashes (48). An expanded risk of bleeding may come from ginkgo's antiplatelet action (49). Major bleeding episodes with ginkgo and antiplatelet and anticoagulant therapy, including subarachnoid and cerebral haemorrhage, have been documented (50).

Grape Seeds (*Vitis vinifera*)

The utilization of grapeseed extricate is accepted to be useful for a variety of cardiovascular diseases, involving atherosclerosis, hypertension, hypercholesterolemia, chronic venous insufficiency, diabetic retinopathy, and neuropathy (GSE). It is well known that grapes contain a lot of antioxidant compounds. For instance, grape seeds have high concentrations of oligomeric proanthocyanidin complexes, vitamin E, flavonoids, and linoleic acid, but resveratrol is mostly found in grape skin (51). According to a study, grape seeds might diminish platelet activity and platelet-dependent inflammatory responses (52). GSE substantially decreased systolic blood pressure (SBP) while having no effect on diastolic blood pressure (DBP), blood lipid levels, or C-reactive protein, according to a meta-analysis of 9 RCTs including 390 people (53). GSE was recently shown to reduce SBP by 5.6% and DBP by 4.7% after 6 weeks of medication contrasted to a placebo in a preliminary of 36 people with pre-hypertension (54). Furthermore, studies indicate that GSE might diminish LDL cholesterol and shield it from oxidation (55). Due to the scant data and the underwhelming results mentioned, there is currently deficient proof to support the utilization of grape seeds for treating any cardiac-related issues. The well-being profile of grape seeds is not notable since there is not enough information to assess it. In RCTs, common negative effects such as tingling, dizziness, nausea, diarrhea, headaches, sore throats, and coughing have been reported (56).

Green Tea (*Camellia sinensis*)

Green tea has been linked to therapeutic therapies for both weight loss and mental clarity. A portion of the proposed cardiovascular advantages incorporates lower cholesterol levels, further developed diabetes control, and the counteraction of cardiovascular events. Many flavonoids, mostly in the form of catechins, may be found in green tea (57). It additionally contains impressive measures of nutrients and minerals, for example, folic corrosive, niacin, pantothenic corrosive, and niacin, as well as riboflavin, manganese, potassium, and magnesium (58). As per huge observational investigations, green tea might decrease cardiovascular morbidity and mortality when consumed frequently (somewhere around three cups each day). A deliberate Cochrane survey that inspected the viability of tea for the essential counteraction of cardiovascular illness contained 11 RCTs, including 7 that took a gander at green tea (59). Green tea use, the researchers found, statistically significantly brings down all total cholesterol, LDL cholesterol, SBP, and DBP.

These conclusions, however, were drawn from a few examinations that looked at various green tea dosages and forms (tea extract in the form of tablets, capsules, bags, packs, or drinks), were short-term (between three and six months), had small sample sizes estimates, and were diversified in terms of the study participants included. A diminished risk of type 2 diabetes mellitus has also been related in cohort studies to the frequent use of green tea. Nonetheless, the aftereffects of RCTs examining what green tea meant for markers of glucose-insulin homeostasis have caused debate (60). In clinical examinations, green tea had all the earmarks of being generally protected. There have been a couple of case reports of liver harm in people who ingested potent green tea extracts, however, these occurrences are very rare and often result in complete recovery once the green tea drinking is discontinued. Additionally, green tea carries unimportant measures of vitamin K, which might diminish the adequacy of anticoagulants like warfarin (61).

Hawthorn (*Crataegus spp.*)

Hawthorn has historically been used to treat renal, heart, and digestive issues. Several cardiovascular issues, together with hypertension, hyperlipidemia, arrhythmia, and congestive heart failure, have been claimed to respond well to hawthorn treatment (62). According to scientific research, hawthorn exhibits antioxidant properties at cellular and mitochondrial levels. The anti-inflammatory properties of this plant would likewise be related to the decreased regulation of inflammatory cytokine intracellular expression. Hawthorn may possibly have a beneficial inotropic effect since it seemed to affect the sodium-potassium (Na/K)-ATPase and enhance calcium transport in cardiomyocytes. It might be antiarrhythmic effects through impacts like that of class III antiarrhythmic drugs. It has been shown that hawthorn has a vasodilator effect on the coronary and peripheral arteries, which may have a direct influence on endothelial NO levels and angiotensin-converting enzyme activity. Hawthorn is reported to offer other anti-atherosclerotic effects, such as lessening endothelial barrier dysfunction, restricting smooth muscle cell migration and proliferation after vascular injury, and decreasing platelet collection. According to some studies, hawthorn may also stop the liver from creating cholesterol and the intestines from absorbing lipids. Despite the large body of research, there is no conclusive evidence that this herb is useful in the treatment of cardiovascular diseases. In those with chronic heart failure, hawthorn might work on several utilitarian parameters, such as maximal workload, left ventricular ejection fraction, practice resilience, and pressure heart rate product. Furthermore, individuals who received hawthorn had much higher symptom improvement than those who received a placebo, including relief from symptoms including shortness of breath, exhaustion, and palpitations.

However, there is currently a paucity of information about hawthorn's effect on challenging cardiac outcomes. Hawthorn was proven to have a positive effect on hypertension in a small number of RCTs, especially when it came to lowering DBP (63). However, owing to the little sample size and the probable absence of force, no inferences on the antihypertensive effects of hawthorn can be taken from such studies. More clinical investigations are expected to enough evaluate these clinical results, much as a small number of RCTs have shown a meaningful effect in bringing down blood cholesterol levels. Clinical examinations have sometimes noted mild adverse effects such as headaches, palpitations, nausea, dizziness, and digestive problems (64). Additionally, early research shows that combining hawthorn with digoxin may intensify the effects of the medication (65).

Milk Thistle (*Silybum marianum*)

Milk thistle has been put forward as a potential natural solution for liver and gallbladder issues. Additionally, there has recent discussion on the potential impact on cardiovascular disease. The notable dynamic active ingredient in milk thistle, silymarin, has a cluster of flavonoids that might be the cause of its powerful anti-inflammatory and antioxidant capabilities. Preclinical studies provide a plethora of knowledge on these characteristics. Recently, it has been shown that silymarin may reduce tissue damage from ischemia and reperfusion, including cardiac injury. This is most likely accomplished by altering pre-conditioning pathways. Clinical examinations on the benefits of milk thistle in treating human cardiovascular issues are insufficient. The idea that milk thistle might be valuable in lessening large cardiovascular threats is based on clinical examinations led on individuals with type 2 diabetes mellitus (66). Silymarin was found to decisively diminish fasting glucose and HbA1c levels while affecting the blood lipid profile in a new meta-examination enveloping five RCTs and 270 diabetic people (67). Investigations did not turn up any noteworthy cardiovascular events. Safety concerns. According to clinical studies, milk thistle is generally well tolerated. Headache, gastrointestinal problems, skin rashes, and allergic responses were the side effects that were most often reported.

Potential markers include SOY (Glycine max) (Glycine max). Soy utilization is accounted for to treat numerous ailments, including menopausal side effects, osteoporosis, mental issues, and disease. It is accepted to bring down cholesterol and blood pressure, which brings down the issues of cardiovascular illness (68). Proteins are found in great abundance in soybeans, the seeds of the soy plant. Additionally, they include isoflavones, which are chemicals with estrogen-like and antiestrogenic properties.

The most often reported negative effects were nausea, gastrointestinal problems, and constipation. Soy and its iso-flavones may increase the risk of thyroid disease, endometrial hyperplasia, breast, ovarian, and uterine cancer, as well as male infertility (69).

Herbal remedies and potential cardiovascular side effects

Notwithstanding those all around referenced, other natural cures used to treat conditions other than cardiovascular illness may likewise raise applicable cardiovascular issues. The FDA removed Ephedra, a dietary supplement for weight reduction that contains ephedrine, off the market in 2004 because it posed a serious chance of cardiovascular events, such as arrhythmias, heart failure, myocardial infarction, changes in blood pressure, and death. Somewhere in the year 1995 and 1997, the FDA got 900 reports about the conceivable results of this medicine, including stroke, myocardial dead tissue, and unexpected passing (70).

Herbal remedies may potentially collaborate with cardiovascular therapies by changing the absorption, distribution, metabolism, and elimination of cardiovascular drugs and impacting how they are distributed and metabolized. For instance, *Salvia miltiorrhiza* has been displayed to lessen the limiting of warfarin to serum egg whites, thus expanding free medication fixations in vivo and expanding the risk of draining altogether. It also acts as an antimicrobial specialist to forestall upper respiratory tract diseases, infections, and the common cold. Cranberries, which are utilized to treat female urinary tract infections, may block the main isoenzyme involved in the metabolism of warfarin, CYP2C9. Consequently, the overall standardized proportion might go up and bleeding risk could rise. St. John's wort and Asian Ginseng, which have been scientifically shown to be successful in the treatment of depression, may, on the other hand, increase CYP activity and decrease the efficacy of medications like warfarin that are metabolized by these enzymes. The plasma quantities of known P-glycoprotein substrates, like digoxin, are impacted by St. John's wort's potential to boost P-glycoprotein activity.

In humans, P-glycoprotein is one of the most important transmembrane transporters. The effects of cardiovascular drugs may be offset by herbal treatments. For instance, the effects of warfarin may be neutralized by green tea, which contains tiny amounts of vitamin K. However, using herbal therapies concurrently may make cardiovascular medications work better. For instance, ginkgo and garlic may reduce platelet function, potentially increasing the risk of bleeding if taken with aspirin or anticoagulants, and European elders may enhance the effects of diuretic drugs. Hawthorn may likewise elevate the blood concentration of digoxin, elevating the occurrence of arrhythmias. Due to the increased risk of hypokalaemia, liquorice usage with a loop or thiazide diuretic medications creates still another concern. Because of the absence of preclinical information and clinical preliminaries that emphasise the impacts of home remedies, post-showcasing studies, which are regularly introduced as case reports or case series, give a large portion of the data on the well-being profiles of natural medications. In this way, laying out an unmistakable connection between subjecting to natural drugs and the potential knock-on effects is preposterous all the time.

Conclusion

The use of herbal treatments to treat cardiovascular issues is not supported by science. Although most herbs influence the biological mechanisms involved in cardiovascular disease, the clinical trials that are now available have limited sample sizes and do not show any impacts on important clinical outcomes. Since insufficient information is currently available, it is not advised to utilize herbal medications in clinical settings. There have also been discussions about possibly relevant adverse effects, such as a higher risk of drug interactions, and it is conceivable that the medicine may have been tainted or changed with another substance. Physicians should learn more about herbal treatments so they can consider the clinical ramifications of using them, discuss any possible advantages and noxious effects with patients, and accentuate that normal is not always necessarily advantageous and secure. The bulk of the herbal remedies examined lack sufficient evidence to support their positive cardiovascular effects. Additionally, results from examination show a constructive outcome on cardiac disorders that are limited by constrained sizes, necessitating confirmation in larger studies. No natural remedies investigated so far might be suggested for treating any cardiovascular issues.

References

1. Wu CH, Wang CC, Tsai MT, et al. Trend and pattern of herb and supplement use in the United States: results from 2002, 2007, and 2012 National Health Interview Surveys. Evid Based Complement Alternat Med 2014;2014:872320.
2. Lord GM, Tagore R, Cook T, et al. Nephropathy caused by Chinese herbs in the UK. Lancet 1999; 354:481–2
3. Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 2006;12:343–6
4. Slim HB, Black HR, Thompson PD. Older blood pressure medications-do they still have a place? Am J Cardiol 2011;108:308–16.
5. Dietary Supplements. U.S. Food and Drug Administration. Available at: http://www.fda. dietary supplements. Accessed January 3, 2017.
6. Herbal Medicinal Products. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl¼pages/regulation/general/general_content_000208.jsp&mid¼WC0b01ac058000240cf. Accessed January 3, 2017.
7. Herbs at a Glance: A Quick Guide to Herbal Supplements. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Center for Complementary and Alternative Medicine, 2010.
8. Naveed, M., Majeed, F., Taleb, A., Zubair, H.M., Shumzaid, M., Farooq, M.A., Baig, M.M., Abbas, M., Saeed, M., & Changxing, L. (2020). A Review of Medicinal Plants in Cardiovascular Disorders: Benefits and Risks. The American journal of Chinese medicine, 48 2, 259-286.

9. Liperoti R, Vetrano DL, Bernabei R, Onder G. Herbal Medications in Cardiovascular Medicine. J Am Coll Cardiol. 2017 Mar 7;69(9):1188-1199. doi: 10.1016/ j.jacc.2016.11.078. Erratum in: J Am Coll Cardiol. 2017 Apr 25;69(16):2103. PMID: 28254182.
10. Panax ginseng. Monograph. Altern Med Rev 2009;14:172–6.
11. Kim JH. Cardiovascular diseases and *Panax ginsen*g: a review on molecular mechanisms and medical applications. J Ginseng Res 2012;36: 16–26.
12. Komishon AM, Shishtar E, Ha V, et al. The effect of ginseng (genus Panax) on blood pressure: a systematic review and meta-analysis of randomized controlled clinical trials. J Hum Hypertens 2016;30:619–26.
13. Gui QF, Xu ZR, Xu KY, et al. The efficacy of ginseng-related therapies in type 2 diabetesmellitus: an updated systematic review and meta- analysis. Medicine (Baltimore) 2016;95:e2584.
14. Shishtar E, Sievenpiper JL, Djedovic V, et al. The effect of ginseng (the genus *Panax*) on gly- cemic control: a systematic review and meta- analysis of randomized controlled clinical trials. PLoS One 2014;9:e107391.
15. Anetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997;54:692–3.
16. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009;69:1777–98.
17. Huang H, Lai S, Wan Q, et al. Astragaloside IV protects cardiomyocytes from anoxia/reoxygenation injury by upregulating the expression of Hes1 protein. Can J Physiol Pharmacol 2016;94:542–53.
18. Zhang BQ, Hu SJ, Qiu LH, et al. Effects of *Astragalus membranaceus* and its main compo- nents on the acute phase endothelial dysfunction induced by homocysteine. Vascul Pharmacol 2007;46:278–85.
19. Yang J, Wang HX, Zhang YJ, et al. Astragalo- side IV attenuates inflammatory cytokines by inhibiting TLR4/NF-lB signaling pathway in isoproterenol-induced myocardial hypertrophy. J Ethnopharmacol 2013;150:1062–70.
20. Han R, Tang F, Lu M, et al. Protective effects of Astragalus polysaccharides against endothelial dysfunction in hypertrophic rats induced by isoproterenol. Int Immunopharmacol 2016;38: 306–12.
21. Luan A, Tang F, Yang Y, et al. Astragalus polysaccharide attenuates isproterenol-induced cardiac hypertrophy by regulating TNF-a/PGC-1a signaling mediated energy biosynthesis. Environ Toxicol Pharmacol 2015;39:1081–90.
22. Lu Y, Li S, Wu H, et al. Beneficial effects of astragaloside IV against angiotensin II-induced mitochondrial dysfunction in rat vascular smooth muscle cells. Int J Mol Med 2015;36:1223–32.
23. Zhou X, Xin Q, Wang Y, et al. Total flavonoids of Astragalus plays a cardioprotective role in viral myocarditis. Acta Cardiol Sin 2016;32:81–8.
24. Luo HM, Dai RH, Li Y. [Nuclear cardiology study on effective ingredients of Astragalus membranaceus in treating heart failure]. Zhong- guo Zhong Xi Yi Jie He Za Zhi 1995;15:707–9.
25. Li SQ, Yuan RX, Gao H. [Clinical observation on the treatment of ischemic heart disease with Astragalus membranaceus]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995;15:77–80.
26. Lei ZY, Qin H, Liao JZ. [Action of Astragalus membranaceus on left ventricular function of angina pectoris]. Zhongguo Zhong Xi Yi Jie He Za Zhi 1994;14:199–202, 195.
27. Goyal A, Sharma V, Upadhyay N, et al. Flax and flaxseed oil: an ancient medicine & modern functional food. J Food Sci Technol 2014;51:1633–53.
28. Anderson JW, Baird P, Davis RH Jr., et al. Health benefits of dietary fiber. Nutr Rev 2009; 67:188–205.
29. Francis AA, Deniset JF, Austria JA, et al. Ef- fects of dietary flaxseed on atherosclerotic plaque regression. Am J Physiol Heart Circ Physiol 2013; 304:H1743–51.
30. Haliga RE, Iancu RI, Butcovan D, et al. Flax- seed prevents leukocyte and platelet adhesion to endothelial cells in experimental atherosclerosis by reducing sVCAM-1 and vWF. Sci World J 2013; 2013:303950.
31. Khalesi S, Irwin C, Schubert M. Flaxseed consumption may reduce blood pressure: a systematic review and meta-analysis of controlled trials [Published correction appears in J Nutr 2015;145: 2633]. J Nutr 2015;145:758–65.
32. Rodriguez-Leyva D, Weighell W, Edel AL, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension 2013;62: 1081–9.
33. Caligiuri SP, Aukema HM, Ravandi A, et al. Flaxseed consumption reduces blood pressure in patients with hypertension by altering circulating oxylipins via an a-linolenic acid-induced inhibition of soluble epoxide hydrolase. Hypertension 2014; 64:53–9.
34. Caligiuri SP, Rodriguez-Leyva D, Aukema HM, et al. Dietary flaxseed reduces central aortic blood pressure without cardiac involvement but through changes in plasma oxylipins. Hypertension 2016; 68:1031–8.
35. Pan A, Yu D, Demark-Wahnefried W. Meta- analysis of the effects of flaxseed interventions on blood lipids. Am J Clin Nutr 2009;90:288–97.
36. Edel AL, Rodriguez-Leyva D, Maddaford TG, et al. Dietary flaxseed independently lowers circulating cholesterol and lowers it beyond theeffects of cholesterol-lowering medications alone in patients with peripheral artery disease. J Nutr 2015;145:749–57.
37. Ander BP, Weber AR, Rampersad PP, et al. Dietary flaxseed protects against ventricular fibrillation induced by ischemia-reperfusion in normal and hypercholesterolemic rabbits. J Nutr2004;134:3250–6.
38. Rahman K, Lowe GM. Garlic and cardiovascular disease: a critical review. J Nutr 2006;136: 736S–40S.
39. Breithaupt-Grögler K, Ling M, Boudoulas H, et al. Protective effect of chronic garlic intake on elastic properties of aorta in the elderly. Circulation 1997; 96:2649–55. Health benefits of dietary fiber. Nutr Rev 2009; 67:188–205.
40. Hou LQ, Liu YH, Zhang YY. Garlic intake lowers fasting blood glucose: meta-analysis of randomized

controlled trials. Asia Pac J Clin Nutr 2015; 24:575–82.
41. Atkin M, Laight D, Cummings MH. The effects of garlic extract upon endothelial function, vascular inflammation, oxidative stress, and insulin resistance in adults with type 2 diabetes at high cardiovascular risk. A pilot double blind randomized placebo-controlled trial. J Diabetes Complications 2016; 30:723–7.
42. Tattelman E. Health effects of garlic. Am Fam Physician 2005; 72:103–6.
43. Zhou W, Chai H, Lin PH, et al. Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular disease. Cardiovasc Drug Rev 2004;22:309–19.
44. Xiong XJ, Liu W, Yang XC, et al. *Ginkgo biloba* extract for essential hypertension: a systemic re- view. Phytomedicine 2014;21:1131–6.
45. Brinkley TE, Lovato JF, Arnold AM, et al., Ginkgo Evaluation of Memory (GEM) Study In- vestigators. Effect of *Ginkgo biloba* on blood pressure and incidence of hypertension in elderly men and women. Am J Hypertens 2010;23: 528–33.
46. Nicolaï SP, Kruidenier LM, Bendermacher BL, et al. *Ginkgo biloba* for intermittent claudication. Cochrane Database Syst Rev 2009;6:CD006888.
47. McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of *Ginkgo biloba* in clinical and preclinical applications. Altern Ther Health Med 2001;7:70–86, 88–90.
48. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombo- cytes by ginkgolides: considerations on possible bleeding complications after oral intake of *Ginkgo biloba* extracts. Phytomedicine 2005;12:10–6.
49. Vale S. Subarachnoid haemorrhage associated with *Ginkgo biloba*. Lancet 1998;352:36.
50. Matthews MK Jr. Association of *Ginkgo biloba* with intracerebral hemorrhage. Neurology 1998; 50:1933–4.
51. Bertelli AA, Das DK. Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 2009;54:468–76.
52. Shafiee M, Carbonneau MA, Urban N, et al. Grape and grape seed extract capacities at pro- tecting LDL against oxidation generated by $Cu^{2þ}$, AAPH or SIN-1 and at decreasing superoxide THP-1cell production. A comparison to other extracts or compounds. Free Radic Res 2003; 37:573–84.
53. Vitseva O, Varghese S, Chakrabarti S, et al. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen in- termediates. J Cardiovasc Pharmacol 2005;46: 445–51.
54. Albers AR, Varghese S, Vitseva O, et al. The antiinflammatory effects of purple grape juice consumption in subjects with stable coronaryartery disease. Arterioscler Thromb Vasc Biol 2004;24:e179–80.
55. Feringa HH, Laskey DA, Dickson JE, et al. The effect of grape seed extract on cardiovascular risk markers: a meta-analysis of randomized controlled trials. J Am Diet Assoc 2011;111:1173–81.
56. Park E, Edirisinghe I, Choy YY, et al. Effects of grape seed extract beverage on blood pressure and metabolic indices in individuals with pre- hypertension: a randomised, double-blinded, two-arm, parallel, placebo-controlled trial. Br J Nutr 2016;115:226–38.
57. Mckeena DJ,Hughes K, Jones K, Green tea monograph, Altern Ther Health Med 2000;6;61-8,70-2, 74
58. Zhang C, Qin YY, Wei X, et al., Tea consumption and risk of cardiovascular outcomes and total mortality; a systematic review and meta-analysis of prospective observational studies, Eur J Epidemiol 2015;30:103-13.
59. Sarma DN, Barett ML, Chavez ML, et al., Safety of green tea extracts: a systematic review by the US Pharmacopoeia. Drug Saf 2008; 31:469-84.
60. Mazzanti G, Di Sotto A, Vitalone A., Hepatotoxicity of green tea: an update. Arch Toxicol 2015; 89:1175-91
61. Stangl V, Lorenz M, Stangl K. The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res 2006;50:218–28.
62. Chang WT, Dao J, Shao ZH., Hawthorn: potential roles in cardiovascular disease, Am J Chin Med 2005;33:1-10.
63. Walker AF, Marakis G, Simpson E, et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomized controlled trial. Br J Gen Pract 2006;56:437–43.
64. Li C, Wang MH, Anti-inflammatory effect of the water fraction from hawthorn fruit on LPS-stimulated RAW 264.7 cells. Nutr Res Pract 2011; 5:101-6.
65. Dasgupta A, Kidd L, Poindexter BJ, et al. Interference of hawthorn on serum digoxin measurements by immunoassays and pharmacodynamic interaction with digoxin. Arch Pathol Lab Med 2010;134:1188–92.
66. Kazazis CE, Evangelopoulos AA, Kollas A, et al. The therapeutic potential of milk thistle in diabetes. Rev Diabet Stud 2014;11:167–74.
67. Surai PF, Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants (Basel) 2015; 4:204-47
68. Gardiner P, Graham RE, Legedza AT, et al. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 2006;166:1968–74.
69. Zholobenko A, Modriansky M, silymarin and its constituents in cardiac preconditioning, Fitoterapia, 2014;97:122-32
70. Onder G, Liperoti R. JAMA Patient Page. Herbal medications. JAMA 2016;315:1068.

*****